Skip to main content
Top
Published in: Calcified Tissue International 5/2013

01-05-2013 | Original Research

Polymorphisms of Muscle Genes Are Associated with Bone Mass and Incident Osteoporotic Fractures in Caucasians

Authors: T. Harsløf, M. Frost, T. L. Nielsen, L. B. Husted, M. Nyegaard, K. Brixen, A. D. Børglum, L. Mosekilde, M. Andersen, L. Rejnmark, B. L. Langdahl

Published in: Calcified Tissue International | Issue 5/2013

Login to get access

Abstract

The interaction between muscle and bone is complex. The aim of this study was to investigate if variations in the muscle genes myostatin (MSTN), its receptor (ACVR2B), myogenin (MYOG), and myoD1 (MYOD1) were associated with fracture risk, bone mineral density (BMD), bone mineral content (BMC), and lean body mass. We analyzed two independent cohorts: the Danish Osteoporosis Prevention Study (DOPS), comprising 2,016 perimenopausal women treated with hormone therapy or not and followed for 10 years, and the Odense Androgen Study (OAS), a cross-sectional, population-based study on 783 men aged 20–29 years. Nine tag SNPs in the four genes were investigated. In the DOPS, individuals homozygous for the variant allele of the MSTN SNP rs7570532 had an increased risk of any osteoporotic fracture, with an HR of 1.82 (95 % CI 1.15–2.90, p = 0.01), and of nonvertebral osteoporotic fracture, with an HR of 2.02 (95 % CI 1.20–3.41, p = 0.01). The same allele was associated with increased bone loss (BMC) at the total hip of 4.1 versus 0.5 % in individuals either heterozygous or homozygous for the common allele (p = 0.006), a reduced 10-year growth in bone area at the total hip of 0.4 versus 2.2 and 2.3 % in individuals heterozygous or homozygous for the common allele, respectively (p = 0.01), and a nonsignificantly increased 10-year loss of total-hip BMD of 4.4 versus 2.7 and 2.9 % in individuals heterozygous or homozygous for the common allele, respectively (p = 0.08). This study is the first to demonstrate an association between a variant in MSTN and fracture risk and bone loss. Further studies are needed to confirm the findings.
Literature
1.
go back to reference Doherty TJ (2003) Aging and sarcopenia. J Appl Physiol 95:1717–1727PubMed Doherty TJ (2003) Aging and sarcopenia. J Appl Physiol 95:1717–1727PubMed
2.
go back to reference Frost HM (1997) Why do marathon runners have less bone than weight lifters? A vital-biomechanical view and explanation. Bone 20:183–189PubMedCrossRef Frost HM (1997) Why do marathon runners have less bone than weight lifters? A vital-biomechanical view and explanation. Bone 20:183–189PubMedCrossRef
3.
go back to reference Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C et al (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333 Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C et al (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333
4.
go back to reference Silventoinen K, Magnusson PK, Tynelius P, Kaprio J, Rasmussen F (2008) Heritability of body size and muscle strength in young adulthood: a study of one million Swedish men. Genet Epidemiol 32:341–349PubMedCrossRef Silventoinen K, Magnusson PK, Tynelius P, Kaprio J, Rasmussen F (2008) Heritability of body size and muscle strength in young adulthood: a study of one million Swedish men. Genet Epidemiol 32:341–349PubMedCrossRef
6.
go back to reference Karasik D, Kiel DP (2010) Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone 46:1226–1237PubMedCrossRef Karasik D, Kiel DP (2010) Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone 46:1226–1237PubMedCrossRef
7.
go back to reference McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R (2003) Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162:1135–1147PubMedCrossRef McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R (2003) Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162:1135–1147PubMedCrossRef
8.
go back to reference Gallegly JC, Turesky NA, Strotman BA, Gurley CM, Peterson CA, Dupont-Versteegden EE (2004) Satellite cell regulation of muscle mass is altered at old age. J Appl Physiol 97:1082–1090PubMedCrossRef Gallegly JC, Turesky NA, Strotman BA, Gurley CM, Peterson CA, Dupont-Versteegden EE (2004) Satellite cell regulation of muscle mass is altered at old age. J Appl Physiol 97:1082–1090PubMedCrossRef
9.
go back to reference Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L, Bhasin S (2008) The effects of myostatin on adipogenic differentiation of human bone marrow–derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem 283:9136–9145PubMedCrossRef Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L, Bhasin S (2008) The effects of myostatin on adipogenic differentiation of human bone marrow–derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem 283:9136–9145PubMedCrossRef
10.
go back to reference McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83–90PubMedCrossRef McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83–90PubMedCrossRef
11.
go back to reference Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W et al (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682–2688PubMedCrossRef Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W et al (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682–2688PubMedCrossRef
12.
go back to reference Elkasrawy MN, Hamrick MW (2010) Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 10:56–63PubMed Elkasrawy MN, Hamrick MW (2010) Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 10:56–63PubMed
13.
go back to reference Zhang ZL, He JW, Qin YJ, Hu YQ, Li M, Zhang H et al (2008) Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families. Osteoporos Int 19:39–47PubMedCrossRef Zhang ZL, He JW, Qin YJ, Hu YQ, Li M, Zhang H et al (2008) Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families. Osteoporos Int 19:39–47PubMedCrossRef
14.
go back to reference Seeman E, Hopper JL, Young NR, Formica C, Goss P, Tsalamandris C (1996) Do genetic factors explain associations between muscle strength, lean mass, and bone density? A twin study. Am J Physiol Endocrinol Metab 270:E320–E327 Seeman E, Hopper JL, Young NR, Formica C, Goss P, Tsalamandris C (1996) Do genetic factors explain associations between muscle strength, lean mass, and bone density? A twin study. Am J Physiol Endocrinol Metab 270:E320–E327
15.
go back to reference Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH (1999) The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 31:207–219PubMedCrossRef Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH (1999) The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 31:207–219PubMedCrossRef
16.
go back to reference Gonzalez-Bofill N, Husted LB, Harslof T, Tofteng CL, Abrahamsen B, Eiken P et al (2011) Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk. Osteoporos Int 22:1145–1156PubMedCrossRef Gonzalez-Bofill N, Husted LB, Harslof T, Tofteng CL, Abrahamsen B, Eiken P et al (2011) Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk. Osteoporos Int 22:1145–1156PubMedCrossRef
17.
go back to reference Nielsen TL, Wraae K, Brixen K, Hermann AP, Andersen M, Hagen C (2006) Prevalence of overweight, obesity and physical inactivity in 20- to 29-year-old, Danish men. Relation to sociodemography, physical dysfunction and low socioeconomic status: the Odense Androgen Study. Int J Obes (Lond) 30:805–815CrossRef Nielsen TL, Wraae K, Brixen K, Hermann AP, Andersen M, Hagen C (2006) Prevalence of overweight, obesity and physical inactivity in 20- to 29-year-old, Danish men. Relation to sociodemography, physical dysfunction and low socioeconomic status: the Odense Androgen Study. Int J Obes (Lond) 30:805–815CrossRef
18.
go back to reference McCloskey EV, Spector TD, Eyres KS, Fern ED, O’Rourke N, Vasikaran S et al (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 3:138–147PubMedCrossRef McCloskey EV, Spector TD, Eyres KS, Fern ED, O’Rourke N, Vasikaran S et al (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 3:138–147PubMedCrossRef
19.
go back to reference Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef
20.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef
21.
go back to reference Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCrossRef Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCrossRef
22.
go back to reference Gonzalez-Freire M, Rodriguez-Romo G, Santiago C, Bustamante-Ara N, Yvert T, Gomez-Gallego F et al (2010) The K153R variant in the myostatin gene and sarcopenia at the end of the human lifespan. Age (Dordr) 32:405–409CrossRef Gonzalez-Freire M, Rodriguez-Romo G, Santiago C, Bustamante-Ara N, Yvert T, Gomez-Gallego F et al (2010) The K153R variant in the myostatin gene and sarcopenia at the end of the human lifespan. Age (Dordr) 32:405–409CrossRef
23.
go back to reference Kostek MA, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS et al (2009) Myostatin and follistatin polymorphisms interact with muscle phenotypes and ethnicity. Med Sci Sports Exerc 41:1063–1071PubMedCrossRef Kostek MA, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS et al (2009) Myostatin and follistatin polymorphisms interact with muscle phenotypes and ethnicity. Med Sci Sports Exerc 41:1063–1071PubMedCrossRef
24.
go back to reference Santiago C, Ruiz JR, Rodriguez-Romo G, Fiuza-Luces C, Yvert T, Gonzalez-Freire M et al (2011) The K153R polymorphism in the myostatin gene and muscle power phenotypes in young, non-athletic men. PLoS One 6:e16323PubMedCrossRef Santiago C, Ruiz JR, Rodriguez-Romo G, Fiuza-Luces C, Yvert T, Gonzalez-Freire M et al (2011) The K153R polymorphism in the myostatin gene and muscle power phenotypes in young, non-athletic men. PLoS One 6:e16323PubMedCrossRef
25.
go back to reference Frost HM (2000) Muscle, bone, and the Utah paradigm: a 1999 overview. Med Sci Sports Exerc 32:911–917PubMed Frost HM (2000) Muscle, bone, and the Utah paradigm: a 1999 overview. Med Sci Sports Exerc 32:911–917PubMed
26.
go back to reference Rauch F, Schoenau E (2001) The developing bone: slave or master of its cells and molecules? Pediatr Res 50:309–314PubMedCrossRef Rauch F, Schoenau E (2001) The developing bone: slave or master of its cells and molecules? Pediatr Res 50:309–314PubMedCrossRef
27.
go back to reference Hamrick MW (2003) Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol 272:388–391PubMedCrossRef Hamrick MW (2003) Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol 272:388–391PubMedCrossRef
28.
go back to reference Hamrick MW, McPherron AC, Lovejoy CO (2002) Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int 71:63–68PubMedCrossRef Hamrick MW, McPherron AC, Lovejoy CO (2002) Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int 71:63–68PubMedCrossRef
29.
go back to reference Hamrick MW, Pennington C, Byron CD (2003) Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res 21:1025–1032PubMedCrossRef Hamrick MW, Pennington C, Byron CD (2003) Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res 21:1025–1032PubMedCrossRef
30.
31.
go back to reference Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M et al (2007) Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow–derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 40:1544–1553PubMedCrossRef Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M et al (2007) Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow–derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 40:1544–1553PubMedCrossRef
32.
go back to reference Hamrick MW, Arounleut P, Kellum E, Cain M, Immel D, Liang LF (2010) Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma 69:579–583PubMedCrossRef Hamrick MW, Arounleut P, Kellum E, Cain M, Immel D, Liang LF (2010) Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma 69:579–583PubMedCrossRef
33.
go back to reference Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB et al (2006) Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 36:22–31PubMedCrossRef Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB et al (2006) Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 36:22–31PubMedCrossRef
34.
go back to reference Bouxsein ML, Seeman E (2009) Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol 23:741–753PubMedCrossRef Bouxsein ML, Seeman E (2009) Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol 23:741–753PubMedCrossRef
35.
go back to reference Beck TJ, Oreskovic TL, Stone KL, Ruff CB, Ensrud K, Nevitt MC et al (2001) Structural adaptation to changing skeletal load in the progression toward hip fragility: the Study of Osteoporotic Fractures. J Bone Miner Res 16:1108–1119PubMedCrossRef Beck TJ, Oreskovic TL, Stone KL, Ruff CB, Ensrud K, Nevitt MC et al (2001) Structural adaptation to changing skeletal load in the progression toward hip fragility: the Study of Osteoporotic Fractures. J Bone Miner Res 16:1108–1119PubMedCrossRef
36.
Metadata
Title
Polymorphisms of Muscle Genes Are Associated with Bone Mass and Incident Osteoporotic Fractures in Caucasians
Authors
T. Harsløf
M. Frost
T. L. Nielsen
L. B. Husted
M. Nyegaard
K. Brixen
A. D. Børglum
L. Mosekilde
M. Andersen
L. Rejnmark
B. L. Langdahl
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 5/2013
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-013-9702-1

Other articles of this Issue 5/2013

Calcified Tissue International 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.